Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
United Therapeutics Corporation's quarterly P/E stands at 15.9x, up 11.6% year-over-year — indicating the stock has re-rated higher or earnings have softened. EV/EBITDA has expanded 20.0% YoY to 12.6x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 18.09 | 15.90 | 14.64 | 11.21 | 11.62 | 14.25 | 14.02 | 13.61 | 9.31 | 12.61 | 10.50 | 10.53 | 11.52 |
| — | +11.6% | +4.4% | -17.7% | +24.9% | +13.0% | +33.6% | +29.3% | -19.2% | -51.6% | -1.5% | -56.9% | +29.2% | |
| P/S Ratio | 6.91 | 7.38 | 6.20 | 4.34 | 4.71 | 5.84 | 5.79 | 5.29 | 4.21 | 4.45 | 4.61 | 4.58 | 5.48 |
| — | +26.5% | +7.1% | -17.9% | +11.9% | +31.1% | +25.7% | +15.5% | -23.1% | -36.3% | -6.8% | -24.5% | +18.3% | |
| P/B Ratio | 3.40 | 3.29 | 3.01 | 1.93 | 2.20 | 2.67 | 2.84 | 2.66 | 2.14 | 1.83 | 1.97 | 2.02 | 2.17 |
| — | +23.3% | +5.8% | -27.2% | +2.9% | +45.7% | +44.7% | +31.5% | -1.4% | -36.1% | -12.1% | -23.1% | +5.8% | |
| P/FCF | 21.13 | 33.67 | 14.10 | 26.79 | 9.70 | 16.88 | 14.42 | 20.22 | 8.44 | 38.02 | 10.01 | 44.35 | 8.33 |
| — | +99.5% | -2.2% | +32.5% | +14.9% | -55.6% | +44.1% | -54.4% | +1.3% | -1.8% | -25.5% | +72.2% | +7.1% | |
| EV / EBITDA | 12.95 | 12.55 | 11.39 | 7.97 | 9.54 | 10.46 | 11.17 | 10.54 | 7.25 | 9.54 | 8.02 | 8.17 | 9.02 |
| — | +20.0% | +1.9% | -24.4% | +31.6% | +9.7% | +39.3% | +29.1% | -19.7% | -47.0% | +4.7% | -38.2% | +26.9% | |
| EV / EBIT | 13.69 | 11.86 | 10.60 | 7.39 | 7.96 | 9.76 | 10.15 | 11.16 | 6.53 | 8.41 | 8.35 | 8.50 | 8.79 |
| — | +21.5% | +4.4% | -33.8% | +21.7% | +16.1% | +21.6% | +31.2% | -25.6% | -54.2% | +7.1% | -53.0% | +18.5% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
United Therapeutics Corporation's operating margin was 45.1% in Q4 2025, down 3.5 pp QoQ and down 3.5 pp YoY. The trailing four-quarter average of 46.9% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 3.1% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 87.9% | 86.9% | 87.4% | 89.0% | 88.4% | 89.7% | 88.9% | 89.1% | 89.2% | 88.4% | 88.5% | 89.3% | 89.7% |
| — | -3.1% | -1.7% | -0.1% | -1.0% | +1.4% | +0.5% | -0.2% | -0.5% | -0.2% | -4.6% | -4.7% | -5.0% | |
| Operating Margin | 46.9% | 45.1% | 48.6% | 45.6% | 48.2% | 48.6% | 45.8% | 44.7% | 52.6% | 42.3% | 53.7% | 52.5% | 56.1% |
| — | -7.1% | +6.1% | +2.0% | -8.3% | +14.9% | -14.6% | -14.8% | -6.3% | +18.4% | -11.9% | +21.6% | -10.0% | |
| Net Margin | 41.9% | 46.1% | 42.4% | 38.8% | 40.6% | 40.9% | 41.3% | 38.9% | 45.2% | 35.3% | 43.9% | 43.5% | 47.5% |
| — | +12.6% | +2.6% | -0.4% | -10.3% | +15.9% | -6.0% | -10.5% | -4.8% | +31.4% | -5.3% | +74.9% | -8.5% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 19.7% | 5.3% | 4.9% | 4.4% | 4.9% | 4.8% | 5.2% | 5.0% | 5.4% | 3.7% | 4.8% | 4.9% | 4.9% |
| — | +10.8% | -6.1% | -12.2% | -10.2% | +29.4% | +8.9% | +2.4% | +11.5% | +31.5% | -10.7% | +80.2% | -17.6% | |
| ROA | 17.5% | 4.8% | 4.4% | 4.0% | 4.3% | 4.2% | 4.5% | 4.2% | 4.5% | 3.1% | 3.9% | 4.0% | 3.9% |
| — | +15.0% | -0.6% | -6.0% | -5.0% | +35.9% | +14.3% | +5.7% | +15.4% | +37.0% | -7.6% | +87.0% | -14.7% | |
| ROIC | 21.1% | 4.9% | 5.3% | 5.1% | 5.7% | 5.4% | 5.3% | 5.0% | 5.3% | 3.6% | 4.7% | 4.7% | 4.5% |
| — | -9.3% | +0.5% | +1.6% | +7.5% | +49.7% | +13.1% | +6.1% | +15.8% | +22.9% | -14.0% | +33.1% | -15.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 25.8% YoY to 6.60x, strengthening the short-term liquidity position.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 0.03 | 0.05 | 0.07 | 0.09 | 0.11 | 0.12 | 0.14 | 0.15 | 0.16 |
| — | — | — | — | -73.9% | -60.2% | -53.2% | -40.6% | -28.0% | -29.9% | -20.1% | -20.2% | -18.5% | |
| Debt / EBITDA | — | — | — | — | 0.57 | 0.79 | 1.10 | 1.48 | 1.62 | 2.56 | 2.35 | 2.45 | 2.69 |
| — | — | — | — | -64.5% | -68.9% | -53.0% | -39.8% | -39.9% | -39.7% | -3.8% | -34.3% | +0.9% | |
| Current Ratio | 6.60 | 6.60 | 6.40 | 7.26 | 5.46 | 5.25 | 4.58 | 4.35 | 3.77 | 4.41 | 4.65 | 8.68 | 9.84 |
| — | +25.8% | +39.6% | +66.9% | +44.7% | +18.9% | -1.5% | -49.9% | -61.6% | -55.2% | -52.0% | +7.2% | +11.3% | |
| Quick Ratio | 6.28 | 6.28 | 6.07 | 6.94 | 5.23 | 5.03 | 4.41 | 4.18 | 3.64 | 4.28 | 4.51 | 8.40 | 9.52 |
| — | +24.7% | +37.6% | +65.8% | +43.9% | +17.8% | -2.1% | -50.2% | -61.8% | -55.2% | -52.0% | +7.3% | +11.5% | |
| Interest Coverage | 76.54 | 115.06 | 129.50 | 49.93 | 62.75 | 45.28 | 33.97 | 27.58 | 26.79 | 17.23 | 20.96 | 21.18 | 20.61 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonUnited Therapeutics Corporation's current P/E is 18.1x. The average P/E over the last 4 quarters is 13.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
United Therapeutics Corporation's current operating margin is 46.9%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking United Therapeutics Corporation's business trajectory between earnings reports.